Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295464 | 0.80 | — | — | |
| Ammonia Solution, Strong SCHEMBL28281906 | 0.78 | KDM4E (0.40) | NPSR1KDM4EMAPK1HIF1APOLB | |
| Hydrochloric Acid SCHEMBL6594526 | 0.78 | KDM4E (0.40) | NPSR1KDM4EMAPK1HIF1APOLB | |
| SCHEMBL14970370 | 0.73 | — | — | |
| SCHEMBL15116744 | 0.72 | GAA (0.30) | — | |
| SCHEMBL10202748 | 0.70 | KDM4E (0.37) | NPSR1KDM4EMAPK1HIF1APOLB | |
| SCHEMBL73996 | 0.68 | — | — | |
| SCHEMBL4439064 | 0.67 | KDM4E (0.39) | NPSR1KDM4EMAPK1HIF1APOLB | |
| SCHEMBL15200246 | 0.67 | KDM4E (0.42) | NPSR1KDM4EMAPK1HIF1APOLB | |
| SCHEMBL10311743 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-03-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | NPSR1 1821/4885KDM4E 3020/4885MAPK1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.